Clinical trials: Colchicine
Coronary Artery Disease, Percutaneous Coronary Intervention
Different Doses of Colchicine on hsCRP
Colchicine reduced atherothrombotic cardiovascular events in the COLCOT and LoDoCo2 studies. US Food and Drug Administration approved colchicine as the first anti-inflammatory drug for cardiovascular diseases on June, 2023.
- Trial name
- NCT06078904
- Testing
- Colchicine 0.5 MG, Colchicine 0.375 MG, Colchicine 0.25 MG
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Healthy
Relative Bioavailability of Colcrys™ 0.6 mg Tablets in Healthy Young and Elderly Volunteers Under Fasted Conditions
The purpose of this study is to evaluate and compare the relative bioavailability of a single dose of Colcrys™ (colchicine) 0.6 mg when administered to a group of young , healthy subjects 18-30 years of age compared to a group of…
- Trial name
- NCT01001052
- Testing
- Colcrys™ (colchicine)
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Cerebral Amyloid Angiopathy, Intracerebral Hemorrhage Lobar
Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage
The goal of this clinical trial is to assess the safety and tolerability of colchicine for preventing intracerebral haemorrhage (ICH) recurrence in patients with cerebral amyloid angiopathy (CAA)-ICH at high risk of recurrence.
- Trial name
- CARE-ICH (NCT07026994)
- Testing
- Colchicine 0.5mg
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- Huashan Hospital
Heart Failure, Inflammation
Colchicine in HFpEF
Heart failure is a growing epidemic that affects up to 500,000 individuals in Canada, with 50,000 new cases being diagnosed each year. Half of these will have HF with preserved ejection fraction (HFpEF).
- Conditions
- Heart Failure, Inflammation, Colchicine
- Trial name
- COLpEF (NCT04857931)
- Testing
- Colchicine
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Montreal Heart Institute
Post COVID Condition
RECLAIM Adaptive Platform Trial for PCC Treatments
RECLAIM is a Phase III, multi-domain, randomized, controlled, adaptive platform trial, designed to evaluate efficacy and safety of repurposed medications in patients with post-COVID condition (PCC).
- Trial name
- RECLAIM (NCT07280572)
- Testing
- Metformin, colchicine
- Where
- Netherlands
- Volunteers
- 1,250 people
- Sponsor
- Janneke van de Wijgert
Myocardial Infarction, Acute
COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction
This study evaluates the benefit of colchicine on induced denervation after myocardial infarction. Patients who have suffered a documented De Novo myocardial infarction and completed a revascularization procedure will receive…
- Trial name
- COLD-MI (NCT04420624)
- Testing
- Colchicine
- Where
- France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Montpellier
Atrial Fibrillation
Colchicine and CRP in Atrial Fibrillation and AF Ablation
Colchicine will lower C-reactive protein (CRP) in chronic atrial fibrillation and reduce the rise in CRP which occurs following atrial fibrillation ablation
- Trial name
- NCT01755949
- Testing
- Colchicine, 0.6 mg PO BID
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mayo Clinic
COVID-19
Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)
Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per UCLA treating physicians versus current care per UCLA treating physicians alone (control arm).
- Trial name
- COLHEART-19 (NCT04355143)
- Testing
- Colchicine Tablets, Current care per UCLA treating physicians
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- University of California, Los Angeles
CABG, Graft Failure
Pilot Trial of Colchicine for Graft Failure in CABG
This is a single-center, prospective, randomized, open-label, assessor-blinded, blank-controlled exploratory (pilot) trial evaluating the feasibility of oral colchicine after coronary artery bypass grafting (CABG).
- Conditions
- CABG, Graft Failure, Colchicine
- Trial name
- CoCAB-Pilot (NCT06802926)
- Testing
- Colchicine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ruijin Hospital
Neutrophils.Hypersegmented | Bld-Ser-Plas, STEMI - ST Elevation Myocardial Infarction
CLEAR SYNERGY Neutrophil Substudy
CLEAR SYNERGY is an international multi center 2x2 randomized placebo controlled trial of colchicine and spironolactone in patients with STEMI.
- Trial name
- NCT03874338
- Testing
- Colchicine Pill
- Where
- United States
- Volunteers
- 322 people
- Sponsor
- NYU Langone Health
Colchicine, Coronary Atherosclerosis Management
Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis
This study aims to investigate whether TET2-associated clonal hematopoiesis of indeterminate potential (TET2-CHIP) can serve as a biomarker to guide precision use of colchicine in a population of clinically stable post-ACS…
- Conditions
- Colchicine, Coronary Atherosclerosis Management, Clonal Hematopoiesis of Indeterminate Potential
- Trial name
- NCT07362966
- Testing
- Colchicine 0.5 mg orally once daily for 12 months., SoC therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenyang Northern Hospital
Arrhythmia
Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients
This study evaluates the role of colchicine in the prevention of atrial fibrillation in patients undergoing open heart surgery. Half of participants will receive colchicine and the other half will not
- Trial name
- END-AF (NCT03021343)
- Testing
- Colchicine
- Volunteers
- 360 people
- Sponsor
- Jordan Collaborating Cardiology Group
Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS)
Ilaris NIS in Korea
This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes…
- Conditions
- Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), Colchicine Resistance Familial Mediterranean Fever (crFMF), TNF Receptor Associated Periodic Syndrome (TRAPS)
- Trial name
- REASSURE (NCT06838143)
- Testing
- Ilaris
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
HIV Infections, Inflammatory Markers
Efficacy and Safety of Low-Dose Colchicine on Surrogate Markers of Cardiovascular Events in People Living With HIV Receiving Antiretroviral Therapy
In a double-blind, randomized controlled trial, we assigned PLWH receiving ART without a history of cardiovascular events to received colchicine 0.6 mg once daily or placebo.
- Conditions
- HIV Infections, Inflammatory Markers, Colchicine Adverse Reaction
- Trial name
- NCT05168137
- Testing
- Low-dose colchicine
- Where
- Thailand
- Volunteers
- 84 people
- Sponsor
- Mahidol University
Amyotrophic Lateral Sclerosis
Colchicine for Amyotrophic Lateral Sclerosis
The study evaluates the effects of two different Colchicine doses (0.01mg/kg/day or 0.005 mg/kg/day) compared to placebo in Amyotrophic Lateral Sclerosis (ALS) patients.
- Trial name
- Co-ALS (NCT03693781)
- Testing
- Colchicine 1 MG Oral Tablet
- Where
- 8 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Coronary Artery Disease
Colchicine Protective Effect in Patients Undergoing Percutaneous Coronary Intervention (COLCHICINE-PROTECT)
The goal of this clinical trial is to evaluate the colchicine protective effect in patients undergoing Percutaneous Coronary Intervention (PCI).
- Trial name
- NCT05739929
- Testing
- Colchicine 0.5 MG Oral Tablet
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- Helwan University
Type 2 Diabetes Mellitus (T2DM), Atherosclerosis
Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes
This study will test whether a low-cost anti-inflammatory medicine called colchicine can help protect the blood vessels of people with type 2 diabetes.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Atherosclerosis, Cardiovascular Diseases
- Trial name
- Col-DM (NCT07837934)
- Testing
- Colchicine 0.5 MG Oral Tablet Once Daily
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- Tan Tock Seng Hospital
Familial Mediterranean Fever
Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients
Colchicine is widely recognized as safe and effective treatment of Familial Mediterranean Fever (FMF) in children and adults. Colchicine is currently used to treat FMF in younger patients by inexact dosing through breaking or…
- Trial name
- NCT01075906
- Testing
- colchicine sprinkle capsules
- Where
- 10 sites in United States, Armenia and 2 more
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Colchicine Resistant/Intolerant Familial Mediterranean Fever
Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)
A study designed to evaluate the role of treatment with a biological agent - Canakinumab in pediatric (age 4-20) Familial Mediterranean Fever (FMF) patients that are intolerant or resistant for colchicine treatment.
- Trial name
- CONTROL FMF (NCT01148797)
- Testing
- Canakinumab
- Where
- 5 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease (CAD)
Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial
This study is a prospective, multicenter, randomized controlled clinical trial designed to evaluate whether an anti-inflammatory medication can help improve heart health in patients with stable coronary artery disease. 1.
- Trial name
- COLOR (NCT07349875)
- Testing
- Colchicine combined with Guideline-Directed Medical Therapy
- Where
- China
- Volunteers
- 3,826 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University